Aytu BioPharma (STU:AY20) ROCE % : 17.77% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aytu BioPharma's annualized ROCE % for the quarter that ended in Sep. 2024 was 17.77%.

Aytu BioPharma ROCE % Historical Data

The historical data trend for Aytu BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma ROCE % Chart

Aytu BioPharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-23.31

-26.42

-34.34

-16.97

-15.11

Aytu BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-36.99	13.91	-15.85	-63.01	17.77

Aytu BioPharma ROCE % Calculation

Aytu BioPharma's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-8.625	/	( ( (125.955 - 63.701)	+	(109.71 - 57.81) )	/ 2 )
	=	-8.625	/	( (62.254	+	51.9)	/ 2 )
	=	-8.625	/	57.077
	=	-15.11 %

Aytu BioPharma's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	8.98	/	( ( (109.71 - 57.81)	+	(104.364 - 55.188) )	/ 2 )
	=	8.98	/	( ( 51.9	+	49.176 )	/ 2 )
	=	8.98	/	50.538
	=	17.77 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Aytu BioPharma (STU:AY20) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aytu BioPharma ROCE % Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AYTU:USA 0A8M:UK

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines